...
首页> 外文期刊>Malaria Journal >Assessment of the therapeutic efficacy of a paediatric formulation of artemether-lumefantrine (Coartesiane?) for the treatment of uncomplicated Plasmodium falciparum in children in Zambia
【24h】

Assessment of the therapeutic efficacy of a paediatric formulation of artemether-lumefantrine (Coartesiane?) for the treatment of uncomplicated Plasmodium falciparum in children in Zambia

机译:儿科蒿甲醚-荧光粉(Coartesiane ?)儿科制剂对赞比亚儿童单纯性恶性疟原虫的治疗效果评估

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Sentinel site surveillance of antimalarials by in-vivo therapeutic efficacy studies in Zambia is one of the key activities ear-marked for monitoring and evaluation. The studies are conducted annually in order to provide timely and reliable information on the status of the recommended regimens for malaria case management. The findings of the therapeutic efficacy of an artemisinin-based combination therapy of pediatric artemether-lumefantrine (Coartesiane?) are reported. Method The design is a simple, one-arm, prospective evaluation of the clinical and parasitological response to directly observed treatment for uncomplicated malaria. The study was conducted in sentinel sites using the WHO standardized protocol for the assessment of therapeutic efficacy of antimalarial drugs (WHO 2000) in children under five years of age, weighing less than 10 Kg. The study was conducted at two clinics, one in Chongwe (Lusaka Province) and Chipata (Eastern Province). The 28-day follow-up period was used coupled with PCR genotyping for MSP1 and MSP2 in order to differentiate recrudescence from re-infections for parasites that appeared after Day 14. Results 91/111 children enrolled in the study, were successfully followed up. Artemether-lumefantrine (Coartesiane?) was found to produce significant gametocyte reduction. The Adequate Clinical and Parasitological Response (ACPR) was found to be 100% (95% CI 96.0;100). Conclusion Coartesiane? was effective in treating uncomplicated malaria in Zambian children weighing less than 10 kg, an age group normally excluded from taking the tablet formulation of artemether-lumefantrine (Coartem?).
机译:背景赞比亚通过体内治疗功效研究对前疟疾进行前哨现场监测是专为监测和评估指定的关键活动之一。这项研究每年进行一次,以提供有关疟疾病例管理推荐治疗方案状况的及时可靠信息。报道了基于青蒿素的小儿蒿甲醚-荧光粉(Coartesiane?)联合治疗的疗效发现。方法该设计是对单纯性疟疾直接观察到的临床和寄生虫学反应的简单,单臂,前瞻性评估。这项研究是使用WHO规范协议在前哨站点进行的,以评估抗疟疾药物对5岁以下体重小于10 Kg的儿童的治疗效果(WHO 2000)。这项研究是在两家诊所进行的,其中一间位于卢萨卡省Chongwe和东部省Chipata。 28天的随访期与MSP1和MSP2的PCR基因分型相结合,以区分复发与第14天后出现的寄生虫再感染之间的区别。结果成功随访了参与研究的91/111名儿童。发现蒿甲醚-荧光黄精(Coartesiane?)可显着减少配子细胞。发现充分的临床和寄生虫反应(ACPR)为100%(95%CI 96.0; 100)。结论Coartesiane?可以有效治疗体重不足10公斤的赞比亚儿童中的单纯性疟疾,该年龄组通常不服用蒿甲醚-卢芬特林(Coartem?)片剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号